Viking Therapeutics Inc Top-Line Results from Phase 2b VOYAGE Study of VK2809 Call Transcript
Good morning, everyone, and welcome to the Viking Therapeutics Phase IIb VOYAGE study top-line data conference call. (Operator Instructions).
As a reminder, this conference call is being recorded today, May 16, 2023. I would now like to turn the floor over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; Marianne Mancini, the company's Chief Operating Officer; and Greg Zante, Viking's Chief Financial Officer.
Before we begin, I'd like to caution that comments made during this conference call today, May 16, 2023, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones.
Forward-looking statements are subject to risks and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |